Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Brazil closed 2025 with a current account deficit equal to 3.02% of GDP, almost unchanged from 3.03% in 2024, central bank figures show. The gap narrowed from an earlier widening to nearly 3.7% of GDP and remained mostly financed by foreign direct investment, which totaled 3.41% of GDP for the year. December data showed a narrower-than-expected cur…
Once Upon a Farm, the organic children’s food company co-founded by actor Jennifer Garner, filed to go public in the U.S., targeting a valuation of up to $764.4 million and seeking to raise nearly $209 million by offering about 11 million shares at $17 to $19 apiece. The company will list on the New York Stock Exchange under the symbol OFRM and has…
IonQ announced plans to acquire SkyWater Technology in a transaction valued at about $1.8 billion, a move that lifted IonQ and SkyWater shares. The deal, offering $15.00 cash and $20.00 in IonQ common stock per SkyWater share, is intended to combine IonQ’s quantum computing capabilities with SkyWater’s U.S.-based semiconductor manufacturing to form…
Canaccord Genuity on January 26, 2026 reiterated a Buy rating on Pacific Biosciences of California (NASDAQ:PACB) and held a $3.00 price target, reflecting roughly 16% upside from the stock's then-current price of $2.58. The share price has rallied recently, trading close to a 52-week high after a strong week of gains. The company reported prelimina…
Canaccord Genuity reaffirmed a Hold rating and a $30 price objective on Caris Life Sciences (NASDAQ: CAI) following the company’s preliminary fourth-quarter and full-year 2025 results. The preliminary numbers outpaced both Canaccord’s estimates and the FactSet consensus by roughly 5% even when omitting revenue from prior period true-ups. Stronger-t…
Canaccord Genuity has reiterated its Buy rating on GRAIL, Inc. (NASDAQ: GRAL) and maintained a $105.00 price target following the company’s preliminary fourth-quarter and full-year 2025 results. The reaffirmation comes as GRAIL reported substantial growth in Galleri testing volume and provided 2026 revenue guidance above analyst expectations at the…
Canaccord Genuity has reiterated a Buy rating on Guardant Health (GH) and maintained a $125.00 price target after the company released preliminary fourth-quarter 2025 results that outperformed both the firm's estimates and the FactSet consensus. The results were driven by growth in Oncology and Shield test volumes, and Canaccord notes Guardant rema…
Forgent Power Solutions Inc. submitted a registration for an initial public offering on the New York Stock Exchange under the symbol FPS. The planned offering amounts to 56 million Class A shares, with a proposed price range of $25.00 to $29.00 per share. The company intends to use proceeds from its portion of the sale to buy common units of its LL…
Santacruz Silver Mining Ltd. saw its stock climb 7% Monday after the company released fourth-quarter 2025 production figures and as silver prices pushed above $110 per ounce. Q4 consolidated output rose on a quarter-over-quarter basis driven by a notable recovery at the Bolívar mine following a May 2025 flooding event, while full-year 2025 producti…
A widespread winter storm delivering snow, sleet and freezing rain left more than 823,000 homes and businesses without electricity early Monday across regions stretching from the Ohio Valley and mid-South to New England. Nashville Electric Service and Entergy were among the hardest hit, while Duke Energy anticipated outages to rise through late Sun…
U.S. stock futures edged slightly lower Monday as traders entered a week that features a Federal Reserve meeting and major tech earnings. Several individual stocks moved notably in premarket trade on merger activity, government investment reports, shifts in commodity prices and corporate announcements, with gold producers and some energy and tech n…
BofA Securities opened coverage of Belite Bio, Inc. ADR (NASDAQ: BLTE) with a Buy rating and a $195 price target, implying roughly an 18% upside from the stock's last quoted price of $164.58. The firm emphasized the commercial opportunity for tinlarebant in Stargardt disease type 1 following positive Phase 3 data, while the company has also priced …
BofA Securities opened coverage of Piper Sandler (NYSE:PIPR) with an Underperform rating and a $385.00 price target, citing constrained potential for outsized EPS growth versus peers tied to larger deals. The firm’s estimates sit below consensus for fiscal years 2026 and 2027, even as Piper Sandler recently posted a significant third-quarter 2025 e…
BofA Securities launched coverage of Moelis (NYSE: MC) with a Neutral rating and an $81 price target, noting the boutique advisory firm's concentrated exposure to M&A revenue and its position as the 14th-largest global M&A advisor. The bank expects deal activity to pick up, but sees relatively more attractive risk/reward profiles elsewhere in its i…
Rothschild Redburn upgraded Meta Platforms Inc. from Neutral to Buy and lifted its price target to $900 from $740, arguing that the stock's long-term upside outweighs short-term spending risks. The firm raised FY26 cost and capital-expenditure estimates, warning of an earnings headwind and a potential temporary dip in consensus EPS to roughly $27-2…
BofA Securities has begun coverage of Evercore Partners (NYSE: EVR) with a Buy rating and a $435.00 price target. The brokerage points to the firm’s standing among boutique investment banks, its ranking in M&A league tables and its private capital business as reasons for optimism. The price objective implies roughly 20% upside from current trading …
BofA Securities began coverage of Lazard (LAZ) with a Buy rating and a $65 price objective, noting the company's significant asset management contribution to revenue, cyclical M&A tailwinds, and progress on a multi-year turnaround. The firm highlighted Lazard's dividend history, recent AUM growth, and management appointments while UBS initiated cov…
Once Upon a Farm, PBC has filed for an initial public offering encompassing 10,997,209 shares priced in a $17 to $19 range, with the company offering 7.6 million shares and existing shareholders selling 3.4 million. At the top end of the proposed price range the offering could bring in up to $209 million. The shares are slated to trade on the New Y…
Analysts at UBS say sources of U.S. growth are narrowing, with much of the economy showing weakness or contraction. The outlook through 2028, they argue, depends heavily on recent surges in artificial intelligence investment concentrated in large technology companies, while consumer spending gains are skewed toward higher-income households.
Evercore ISI upgraded Cisco to Outperform and increased its price target to $100 from $80, arguing the company is positioned for multi-year high single-digit sales growth and low-teens EPS growth. The firm highlighted an accelerating enterprise networking cycle, AI-related revenue potential, product momentum, and recovering traditional markets as t…
Evercore ISI has maintained an Outperform rating and a $112.00 price target on Boston Scientific (BSX), elevating the stock to its Tactical Outperform list ahead of the company’s fourth-quarter results. The firm views short-term concerns about procedure volumes and market reaction to Boston Scientific’s acquisition of Penumbra as overblown, pointin…
Raymond James has reaffirmed an Outperform rating and a $600.00 price target on Microsoft (MSFT) ahead of the company’s fiscal second-quarter 2026 earnings report scheduled for January 28 after market close. The firm cites strong Azure performance and ongoing revenue growth but flags industry-level memory availability and pricing risks that could p…
Raymond James trimmed its price objective for Meta Platforms to $800 from $825 while retaining a Strong Buy rating, calling the company an "AI Tweener" whose near-term valuation will hinge on artificial intelligence developments amid likely higher expenses and capital spending. The firm still forecasts above-consensus revenue growth for 2026 and 20…
Truist Securities reduced its price objective for ProLogis to $139 from $142 while retaining a Buy rating. The broker modestly lowered its 2026 and 2027 normalized funds from operations (FFO) estimates, yet projects accelerating earnings and values the shares as offering roughly 12.5% total return potential without multiple expansion. Recent fourth…
Oppenheimer upgraded Relay Therapeutics (RLAY) from Perform to Outperform and set a $14.00 price target, citing what it calls a "beatable bar" should the VIKTORIA-1 trial for gedatolisib disappoint. The move follows Relay interim data for zovegalisib and continued analyst interest, while InvestingPro metrics show the shares near fair value after st…
